IDEAS home Printed from https://ideas.repec.org/a/spr/aphecp/v8y2010i4p267-280.html
   My bibliography  Save this article

Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada

Author

Listed:
  • Sandra Tunis
  • Luc Sauriol
  • Michael Minshall

Abstract

These findings should be interpreted within the context of a large degree of uncertainty and of several study limitations that include a single clinical trial as the source for primary treatment assumptions and a single province as the source for most cost inputs. Under current study assumptions and limitations, insulin glargine plus OADs was projected to be a cost-effective option, compared with premixed insulin only, for the treatment of insulin-naive patients with type 2 diabetes unresponsive to OADs. Additional work is needed to examine the generalizability of the findings to individual jurisdictions of the Canadian healthcare system. Copyright Adis Data Information BV 2010

Suggested Citation

  • Sandra Tunis & Luc Sauriol & Michael Minshall, 2010. "Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada," Applied Health Economics and Health Policy, Springer, vol. 8(4), pages 267-280, July.
    • Handle: RePEc:spr:aphecp:v:8:y:2010:i:4:p:267-280
    DOI: 10.2165/11535380-000000000-00000
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/11535380-000000000-00000
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.2165/11535380-000000000-00000?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Philip Clarke & Alastair Gray & Rury Holman, 2002. "Estimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62)," Medical Decision Making, , vol. 22(4), pages 340-349, August.
    2. Elkan F. Halpern & Milton C. Weinstein & Maria G.M. Hunink & G. Scott Gazelle, 2000. "Representing Both First- and Second-order Uncertainties by Monte Carlo Simulation for Groups of Patients," Medical Decision Making, , vol. 20(3), pages 314-322, July.
    3. Elise Pelletier & Paula Smith & Kristina Boye & Derek Misurski & Sandra Tunis & Michael Minshall, 2008. "Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting," Applied Health Economics and Health Policy, Springer, vol. 6(2), pages 103-112, July.
    4. Elisabeth Fenwick & Andrew Briggs, 2007. "Cost-Effectiveness Acceptability Curves in the Dock," Medical Decision Making, , vol. 27(2), pages 93-95, March.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Véronique Raimond & Jean-Michel Josselin & Lise Rochaix, 2014. "HTA Agencies Facing Model Biases: The Case of Type 2 Diabetes," PharmacoEconomics, Springer, vol. 32(9), pages 825-839, September.
    2. Xinyang Hua & Thomas Wai-Chun Lung & Andrew Palmer & Lei Si & William H. Herman & Philip Clarke, 2017. "How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic Review," PharmacoEconomics, Springer, vol. 35(3), pages 319-329, March.
    3. Asrul Akmal Shafie & Chin Hui Ng & Yui Ping Tan & Nathorn Chaiyakunapruk, 2017. "Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus," PharmacoEconomics, Springer, vol. 35(2), pages 141-162, February.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Neale Cohen & Michael Minshall & Lyn Sharon-Nash & Katerina Zakrzewska & William Valentine & Andrew Palmer, 2007. "Continuous Subcutaneous Insulin Infusion versus Multiple Daily Injections of Insulin," PharmacoEconomics, Springer, vol. 25(10), pages 881-897, October.
    2. Sun-Young Kim & Sue Goldie, 2008. "Cost-Effectiveness Analyses of Vaccination Programmes," PharmacoEconomics, Springer, vol. 26(3), pages 191-215, March.
    3. Montserrat Vera-Llonch & Ellen Dukes & Javier Rejas & Oleg Sofrygin & Marko Mychaskiw & Gerry Oster, 2010. "Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(1), pages 35-44, February.
    4. Mason, J.E. & Denton, B.T. & Shah, N.D. & Smith, S.A., 2014. "Optimizing the simultaneous management of blood pressure and cholesterol for type 2 diabetes patients," European Journal of Operational Research, Elsevier, vol. 233(3), pages 727-738.
    5. Elizabeth G Bond & Lusine Abrahamyan & Mohammad K A Khan & Andrea Gershon & Murray Krahn & Ping Li & Rajibul Mian & Nicholas Mitsakakis & Mohsen Sadatsafavi & Teresa To & Petros Pechlivanoglou & for t, 2020. "Understanding resource utilization and mortality in COPD to support policy making: A microsimulation study," PLOS ONE, Public Library of Science, vol. 15(8), pages 1-16, August.
    6. Mehdi Najafzadeh & Carlo Marra & Eleni Galanis & David Patrick, 2009. "Cost Effectiveness of Herpes Zoster Vaccine in Canada," PharmacoEconomics, Springer, vol. 27(12), pages 991-1004, December.
    7. Niklas Zethraeus & Magnus Johannesson & Bengt Jönsson & Mickael Löthgren & Magnus Tambour, 2003. "Advantages of Using the Net-Benefit Approach for Analysing Uncertainty in Economic Evaluation Studies," PharmacoEconomics, Springer, vol. 21(1), pages 39-48, January.
    8. Antonio García-Ruiz & Lucía Pérez-Costillas & Ana Montesinos & Javier Alcalde & Itziar Oyagüez & Miguel Casado, 2012. "Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses," Health Economics Review, Springer, vol. 2(1), pages 1-12, December.
    9. Maria Alva & Alastair Gray & Borislava Mihaylova & Philip Clarke, 2014. "The Effect Of Diabetes Complications On Health‐Related Quality Of Life: The Importance Of Longitudinal Data To Address Patient Heterogeneity," Health Economics, John Wiley & Sons, Ltd., vol. 23(4), pages 487-500, April.
    10. Brian T. Denton & Murat Kurt & Nilay D. Shah & Sandra C. Bryant & Steven A. Smith, 2009. "Optimizing the Start Time of Statin Therapy for Patients with Diabetes," Medical Decision Making, , vol. 29(3), pages 351-367, May.
    11. Klemen Naveršnik, 2015. "Output correlations in probabilistic models with multiple alternatives," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(2), pages 133-139, March.
    12. Adrian Bagust & Sophie Beale, 2005. "Modelling EuroQol health‐related utility values for diabetic complications from CODE‐2 data," Health Economics, John Wiley & Sons, Ltd., vol. 14(3), pages 217-230, March.
    13. Derek Misurski & Maureen Lage & Rosalind Fabunmi & Kristina Boye, 2009. "A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine," Applied Health Economics and Health Policy, Springer, vol. 7(4), pages 245-254, December.
    14. Shuyan Gu & Yuhang Zeng & Demin Yu & Xiaoqian Hu & Hengjin Dong, 2016. "Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China," PLOS ONE, Public Library of Science, vol. 11(11), pages 1-21, November.
    15. Xiao Li & Joke Bilcke & Alike W. van der Velden & Robin Bruyndonckx & Samuel Coenen & Emily Bongard & Muirrean de Paor & Slawomir Chlabicz & Maciek Godycki-Cwirko & Nick Francis & Rune Aabenhus & Hein, 2023. "Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(6), pages 909-922, August.
    16. Sankararaman, S. & Mahadevan, S., 2013. "Separating the contributions of variability and parameter uncertainty in probability distributions," Reliability Engineering and System Safety, Elsevier, vol. 112(C), pages 187-199.
    17. Mark Oppe & Maiwenn Al & Maureen Rutten-Mölken, 2011. "Comparing Methods of Data Synthesis," PharmacoEconomics, Springer, vol. 29(3), pages 239-250, March.
    18. Shuyan Gu & Yiming Mu & Suodi Zhai & Yuhang Zeng & Xuemei Zhen & Hengjin Dong, 2016. "Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China," PLOS ONE, Public Library of Science, vol. 11(11), pages 1-25, November.
    19. Vinaytosh Mishra & Mohita G. Sharma, 2020. "Understanding Humanitarian Supply Chain Through Causal Modelling," South Asian Journal of Business and Management Cases, , vol. 9(3), pages 317-329, December.
    20. Sarazin, Gabriel & Morio, Jérôme & Lagnoux, Agnès & Balesdent, Mathieu & Brevault, Loïc, 2021. "Reliability-oriented sensitivity analysis in presence of data-driven epistemic uncertainty," Reliability Engineering and System Safety, Elsevier, vol. 215(C).

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:aphecp:v:8:y:2010:i:4:p:267-280. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.